Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial.
Macete EV, Sacarlal J, Aponte JJ, Leach A, Navia MM, Milman J, Guinovart C, Mandomando I, López-Púa Y, Lievens M, Owusu-Ofori A, Dubois MC, Cahill CP, Koutsoukos M, Sillman M, Thompson R, Dubovsky F, Ballou WR, Cohen J, Alonso PL. Macete EV, et al. Among authors: koutsoukos m. Trials. 2007 Mar 26;8:11. doi: 10.1186/1745-6215-8-11. Trials. 2007. PMID: 17386091 Free PMC article.
Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults.
Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O, Moris P, De Kock E, Clement F, Dubois MC, Koutsoukos M, Demoitié MA, Cohen J, Ballou WR. Leroux-Roels I, et al. Among authors: koutsoukos m. Clin Vaccine Immunol. 2010 Nov;17(11):1763-71. doi: 10.1128/CVI.00133-10. Epub 2010 Sep 22. Clin Vaccine Immunol. 2010. PMID: 20861328 Free PMC article. Clinical Trial.
Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
Lalvani A, Moris P, Voss G, Pathan AA, Kester KE, Brookes R, Lee E, Koutsoukos M, Plebanski M, Delchambre M, Flanagan KL, Carton C, Slaoui M, Van Hoecke C, Ballou WR, Hill AV, Cohen J. Lalvani A, et al. Among authors: koutsoukos m. J Infect Dis. 1999 Nov;180(5):1656-64. doi: 10.1086/315074. J Infect Dis. 1999. PMID: 10515829 Clinical Trial.
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD, Sow SO, Mbaye KD, Thiongane A, Ndiaye BP, Ndour CT, Mboup S, Keshinro B, Kinge TN, Vernet G, Bigna JJ, Oguche S, Koram KA, Asante KP, Gobert P, Hogrefe WR, De Ryck I, Debois M, Bourguignon P, Jongert E, Ballou WR, Koutsoukos M, Roman F; Zaire EBola Research Alliance group. Tapia MD, et al. Among authors: koutsoukos m. Lancet Infect Dis. 2020 Jun;20(6):719-730. doi: 10.1016/S1473-3099(20)30019-0. Epub 2020 Mar 19. Lancet Infect Dis. 2020. PMID: 32199492 Clinical Trial.
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD, Sow SO, Ndiaye BP, Mbaye KD, Thiongane A, Ndour CT, Mboup S, Ake JA, Keshinro B, Akintunde GA, Kinge TN, Vernet G, Bigna JJ, Oguche S, Koram KA, Asante KP, Hogrefe WR, Günther S, Naficy A, De Ryck I, Debois M, Bourguignon P, Jongert E, Ballou WR, Koutsoukos M, Roman F; Zaire EBola Research Alliance group. Tapia MD, et al. Among authors: koutsoukos m. Lancet Infect Dis. 2020 Jun;20(6):707-718. doi: 10.1016/S1473-3099(20)30016-5. Epub 2020 Mar 19. Lancet Infect Dis. 2020. PMID: 32199491 Clinical Trial.
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garçon N, Leroux-Roels G. Vandepapelière P, et al. Among authors: koutsoukos m. Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14. Vaccine. 2008. PMID: 18272264 Clinical Trial.
Vaccine-induced HIV seropositivity: a problem on the rise.
Van Braeckel E, Koutsoukos M, Bourguignon P, Clement F, McNally L, Leroux-Roels G. Van Braeckel E, et al. Among authors: koutsoukos m. J Clin Virol. 2011 Apr;50(4):334-7. doi: 10.1016/j.jcv.2011.01.003. J Clin Virol. 2011. PMID: 21300566 Clinical Trial.
Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.
Lichterfeld M, Gandhi RT, Simmons RP, Flynn T, Sbrolla A, Yu XG, Basgoz N, Mui S, Williams K, Streeck H, Burgett-Yandow N, Roy G, Janssens M, Pedneault L, Vandepapelière P, Koutsoukos M, Demoitié MA, Bourguignon P, McNally L, Voss G, Altfeld M. Lichterfeld M, et al. Among authors: koutsoukos m. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):1-9. doi: 10.1097/QAI.0b013e3182373b77. J Acquir Immune Defic Syndr. 2012. PMID: 21963936 Free PMC article. Clinical Trial.
52 results